annb0t
Top 20
ResMed RMD continues to see improvement in patient diagnosis trends in sleep apnea, COPD and asthma. However, pricing pressure and FX headwinds weigh on the stock. ResMed carries a Zacks Rank #3 (Hold).
In the past year, ResMed has outperformed its industry. The stock has gained 7.1% against a 22.7% decline of the industry.
ResMed exited the third quarter of fiscal 2023 with better-than-expected earnings and revenues. Revenue growth reflected improved availability of sleep devices to support...
>>> Read more: ResMed's (RMD) New Buyout Aids Growth Amid Rising Costs
In the past year, ResMed has outperformed its industry. The stock has gained 7.1% against a 22.7% decline of the industry.
ResMed exited the third quarter of fiscal 2023 with better-than-expected earnings and revenues. Revenue growth reflected improved availability of sleep devices to support...
>>> Read more: ResMed's (RMD) New Buyout Aids Growth Amid Rising Costs
